Država: Japan
Jezik: engleski
Izvor: すりの適正使用協議会 RAD-AR Council, Japan
Bendamustine hydrochloride hydrate
TOWA PHARMACEUTICAL CO., LTD.
Bendamustine hydrochloride hydrate
injection
Drug Information Sheet("Kusuri-no-Shiori") Injection Revised: 03/2023 The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment. BRAND NAME: BENDAMUSTINE HYDROCHLORIDE INTRAVENOUS INFUSION 100MG/4ML "TOWA" ACTIVE INGREDIENT: Bendamustine hydrochloride hydrate DOSAGE FORM: injection IMPRINT OR PRINT ON WRAPPING: EFFECTS OF THIS MEDICINE This medicine suppresses cancer cell growth through multiple mechanisms, including DNA damage by alkylation and induction of apoptosis. It is usually used to treat indolent B-cell non-Hodgkin's lymphoma, mantle cell lymphoma, and relapsed or refractory diffuse large B-cell lymphoma. It is also used as a pretreatment for tumor-specific T-cell infusion therapy. THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS MEDICINE.BE SURE TO TELL YOUR DOCTOR AND PHARMACIST. ・If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines or foods. If you have myelosuppression, infection, or liver or kidney disorder. If you have heart disorder or have a history of it. If you have a history of hepatitis B. ・If you are pregnant, possibly pregnant or breastfeeding. ・If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.) DOSING SCHEDULE (HOW TO TAKE THIS MEDICINE) ・ Your dosing schedule prescribed by your doctor is(( to be written by a healthcare professional )) ・For indolent B-cell non-Hodgkin's lymphoma: [Combination therapy with anti-CD20 antibody] In general, administer by intravenous infusion once a day f Pročitajte cijeli dokument